MTOR and skin cancer: A mammalian target of rapamycin (mTOR) inhibitor was commenced post-LT in 23/158 patients (14.6%): 16 prophylactically before development of recurrent HCC, three after diagnosis of recurrent HCC, and four for reasons unrelated to HCC (two for skin cancers, two for renal function preservation).